uated with regard to diabetes and osteoporosis. Dexamethasone (DEX) and methylprednisolone (MP) were used as comparative drugs. While DEX-injection for 24 weeks developed severe weight loss, unstable blood glucose, and bone loss, SP-injection did not affect blood glucose and bone mass. MP-injec-66 weeks, MP-injection caused unstable blood glucose, alleviation in the age-related increase of body weight, and bone weakness, which was featured by reduction in collagen deposition and trabecular bone volume based on histological and micro CT analysis. However, SP-injection for 66 weeks rather increased collagen deposition, bone volume, and bone density. Therefore, this comparative study suggests that SP, even after long-term usage of effective dose, may not cause side effects such as osteoporosis in compari--er for long-term treatment.
INTRODUCTION
The neuro-immune axis is a bidirectional pathway of intersystem connection. Immune responses affect neural function, and in turn, neural activity changes immunologic function (O'Connor et al., 2004) . These systems are mutually regulated via common ligands and their receptors. Of those ligands, Substance-P (SP), distributed in the central nervous system (CNS) and peripheral nervous system (PNS), has functions as a neurotransmitter and as a neuromodulator (Harrison and Geppetti, 2001; Datar et al., sory nerve endings are heavily innervated near bone marrow stroma (Yamazaki and Allen, 1990; Rameshwar et al., 1997) , SP was proposed to play an important role as a mediator of the neuro-immune modulation in the bone marrow (Rameshwar et al., 2001) . SP is composed of 11 amino acids whose sequence is identical in human, rabbit, rat, and mouse (NCBI access #M68909, X62994 and NM013998 respectively) and belongs to the tachykinin neuropeptide family, which is released by a variety of stressful stimuli and tissue injury (Spiegel et al., 2008; ). SP's biological effect is mainly mediated through NK1 receptor (NK-1R) by activating G-protein coupled signaling pathway as well as MAPK pathway (Yang et al., 2002; ing neurotransmitter of sensory neuron in dorsal horns of spinal cord (Budai, 2000) , its expression is also detected in a variety of non-neuronal cells such as monocyte, lymphocyte, neutrophil, epithelial cells, fibroblasts, and so on and its receptors (NK1-R 1, 2, 3) are also expressed in non-neural cells such as bone marrow stromal cells (BMSC) and immune cells (Quartara and Maggi, 1997; Ho et al., 1997; Bost et al., 1992; . From those diversities in tissue distribution of SP and its receptors and strong sequence conservation of SP peptide -ical effects regarding SP and its signaling was expected in non-neural cells.
In addition to neuro-immune function of SP, a new role mobilize BMSC from the bone marrow to the injured tissue (Hong et al. , the alkali-burned corneal injury, in which SP treatment accelerated the healing rate by recruitment of BMSC to wounded site . Furthermore, SP also -sue injury, as shown in radio-induced BM and gastro-intestinal (GI) damages (Kang et al., 2009; Kim et al., , 2010 An et al., 2011) and spinal cord injury (Jiang et al., 2012 (Jiang et al., , 2013 . Multifunctional effects of SP in the process of wound healing propose the SP-peptide as a candidate -ease as well as facilitating tissue repair.
Steroids such as DEX, MP, and triamcinolone are curundesired side effects after long-term use such as steroidinduced diabetes (SID), osteoporosis, and strong immune suppression have been serious clinical problems (Hwang and Weiss, 2003) . Among them, osteoporosis, which is characterized by low bone mass and abnormal bone micro-architecture with a concomitant increase in bone fragility and susceptibility to fractures, is the most serious side effect for morbidity and mortality (Browner et al., 1996; Caliri et al., 2007) . Thus, osteoporotic side effect -This study aims to estimate whether SP, with capaci---cemia after its long-term use or not. Furthermore, those long-term effects of SP were comparatively analyzed with clinic by measuring blood glucose level, body weight, bone density and bone volume, and collagen deposition in the rat bone sections after three times per week iv injec-
MATERIALS AND METHODS

Materials
SP was purchased from Calbiochem (Darmstadt, Germany; purity 96%), DEX from Jeil Pharma company (Seoul, Korea, purity 97%), MP from Kunwha Pharma company (Seoul, Korea, purity 98 %).
Animal experiment
Male SD rats at the age of 6 weeks were purchased from Orient Bio (Seoul, Korea). Animals were mainan animal holding room and allowed acclimatize to new environment for a period of 1 week before starting the experiment. All animals received standard rat chow and water ad libitum. All animal works were approved by the institutional animal use committee of Kyung Hee University with the approval number; KHUASP (SU)-10-010.
Administration of SP, DEX, and MP
SP was intravenously injected to rat tail vein in the of MP, corresponding to clinically used doses (Bronicki et al., 2000; Jared et al., 2013) . Intravenous injection was performed three times per week, for 24 weeks for DEX (n = 3) and 66 weeks for MP (n = 5).
Measurement of body weight and blood glucose
Body weight was checked every week. For measurement of blood glucose, 10 μl of blood was collected from tail vein and glucose level was assessed using Accu-Check Active (Roche, Mannheim, Germany) once a week.
Histological analysis
Rats were sacrificed and both femurs were isolated. Left femur was decalcified in 0.2 M EDTA for 2 weeks and processed using a TP1020 (Leica Biosystems, Wetzlar, Germany) to make paraffin blocks. The right femur was analyzed for bone density using micro CT (Skyscan TM CT-analyzer software, Bruker, MA, USA).
Hematoxylin & Eosin (H&E) staining
Paraffin sections (4 μm thickness) were stained with H&E staining reagents (Sigma-Aldrich St Louis, -ple was deparaffinized with xylene, serially hydrated with alcohol, and treated with hematoxylin for 5 min and eosin for 2 min. After phosphate buffered saline (PBS) washing, samples were mounted and observed under microscope, BX41 (Olympus Co., Tokyo, Japan).
Masson trichrome (MTC) Staining
MTC Staining (IHC World, Woodstock, MD, USA) Vol. 39 No. 3 was performed according to the instructions from the bouin's solution (Sigma-Aldrich) for 1 hr at 56°C. After washing in distilled water, sections were serially stained with Weigert' hematoxylin for 10 min, biebrich scarlet-acid fuchsin for 2 min, phosphomolybdic-phosphotungstic acid solution for 10 min, and aniline blue for 5 min. After washing with distilled water, 1% acetic acid (Sigma-Aldrich) was treated for 5 min. Finally, samples were dehydrated and mounted. (nuclei: black, cytoplasm, keratin, muscle: red, collagen: blue).
Measurement of bone ALP
Whole blood was collected to separate the serum. Bone ALP in the serum was analyzed using BS-400 (Mindray, China) according to the method of enzyme kinetics.
Measurement of bone density
hr and analyzed by micro-CT (Skyscan TM CT-analyzer software, Bruker, MA, USA). The bone density, trabecular number, trabecular space, bone volume of trabecular volume, trabecular thickness, compact bone volume, and compact bone thickness were measured and quanti-
Statistical analysis
Data were analyzed using Student's t-test and analysis of variance as appropriate. A P-value of 0.05 was consid-S.D. (*p < 0.05, **p < 0.01, ***p < 0.001).
RESULTS
Comparative study of SP and DEX treatment for 24 weeks in the blood glucose, body weight, and bone mass SP or DEX was intravenously injected to rat every other day, three times a week for 24 weeks and the change of body weight and blood glucose were checked every week. Osteotoxicity of SP or steroids were planned to be longer as much as possible. Therefore, we decided the treatment time (~ 24 weeks) for comparative study of SP and Dex based on severity of vital signs and body weight of Dex-treatment group. PBS was injected as a vehicle control (Fig. 1) . SP-injected group and PBS-injected group did not show statistical difference in the body weight or blood glucose level. However, DEX-injected group reduced the age-related increase in body weight, corresponding to approximately 45% less body weight of --ver, histological analysis by H&E staining revealed that DEX-injected group developed typical osteoporosis featured by excessive collagen loss in the bone. In contrast, SP-injected group did not induce collagen degradation but rather increased accumulation of collagen (Fig. 1c) . Thus, SP treatment for 24 weeks did not develop hyperglycemia and osteoporosis, in contrast to severe bone loss, weight loss, and unstable blood glucose level after DEX treatment.
Comparative study of SP and MP treatment for 66 weeks in the blood glucose, body weight, and bone mass
In comparative study of SP with DEX, DEX-induced side effect was very severe. In the case of MP treatment group, good vital sign was maintained up to 60 weeks but after that period, body weight did not keep constant level. We determined treatment time (~66 weeks) for comparative study of SP and MP 66 weeks. Long-term effect of SP was compared with MP for 66 week treatment. SP or MP was intravenously injected to rats three times a week for 66 weeks and the change of body weight and blood glucose were observed every week (Fig. 2) . SP-injection seemed to decrease body weight a bit at early stage but rather increase at later stage, in which no statistical sig--ed the age-related increase of body weight, corresponding to approximately 30% less than PBS-injected group (Fig. 2a) . Blood glucose level in SP and PBS-inject--ed groups throughout the test period (Fig. 2b) . This data suggests that SP may not affect body weight and blood glucose level even though SP was applied for more than 1 year.
In order to check the effect of SP on bone loss, which is one of major unwanted effects of steroids, femur of compare the bone morphology in the trabecular bone anastomosis (TBA). Much thicker and denser deposition than PBS-injected group and MP-injected group. Especially, MP-injected group showed obviously the lower bone density, loosely aligned collagen deposition, and the -ed group (Fig. 2c) . The bone thickness, based on eosinstained area, was measured using image J program. The bone thickness of SP-injected group showed 130% more but MP-injected group showed 27% less than PBS-in-jected group (Fig. 2d) . Moreover, SP-injected group was ilarly to PBS-injected group but MP-injected group was in TBA interspace. positive bone matrix, MTC staining was performed (Fig. 2e) . PBS-injected group showed MTC-blue and MTC-red parts in similar portion and SP-injected group showed more MTC-blue which indicates new collagen deposition in the bone matrix than any other group. In contrast, MP-injected group showed more MTC-red non- p < 0.01, ***: p < 0.001). PBS; phosphate buffered saline, SP; Substance-P, MP; methylprednisolone. Vol. 39 No. 3 collagenous area in the bone matrix. From this result, SP may not cause side effects such as osteoporosis or osteomalacia but rather increase the bone density in the longterm use. Meanwhile, MP was speculated to induce osteoporosis by inducing collagen degradation.
Comparison of circulating bone-ALP between SP-and MP-injected groups after their long-term treatments
uct of osteoclasts and its circulating form has a relatively long half-life (Price, 1993) . Therefore, increased bone-ALP level is associated with an increased risk of rapid bone loss (Ross and Knowltin, 1998; Rogers et al., 2000) and has been a useful indicator for metabolic bone disease.
The effect of SP or MP on the secretion of the bone-ALP was examined in the rat peripheral blood (Fig. 3) . SP-injection showed the lower bone ALP in the serum (not statistically significant) but MP-injection significantly elevated the bone-ALP in the serum, approximately 40% higher than that of PBS-injected group. Higher bone-ALP in the MP-injected group suggests that osteoclast activity related to the bone resorption may be dominant over other group after long-term MP treatment. ALP elevation, as shown in the MP-treated group, may be caused by osteoclast activation related to the osteoporosis or a variety of liver disease such as cholestasis, cholecystitis, cholangitis, cirrhosis, primary biliary cirrhosis, hepatitis, fatty liver and sarcoidosis. However, as judged from micro CT results, histological data of bone sections, subsequent osteoporosis. Most importantly, SP-long-term treatment is not associated with the higher bone ALP level and bone loss.
Comparison of SP-and MP-long-term injections on the bone density based on micro-CT
Histological analysis of bone sections and the bone ALP level in the serum implies that SP may not provoke osteoporotic side effect after its long-term usage. To determine the bone density more quantitatively, the rat femur from each group was analyzed with micro-CT (Fig.  4) . The representative images of trabecular bone and compact bone of bone marrow from each group were shown respectively (Fig. 4a) . TBA was mostly affected by MP long-term treatment comparing to compact bone but not affected by SP treatment. Bone density was analyzed by measuring trabecular bone thickness (Tb.Th), bone vol-(Tb.N), and trabecular space (Tb. Sp) (Fig. 4b) . Quantitative analysis of micro-CT data showed that Tb.Th and TV was lower in MP-injected group than PBS-injected group.
The data collectively suggest that SP may have osteogenesis effect rather than osteoporosis side effect as shown in MP and DEX treatment, which support the safety of SP in the long-term usage.
DISCUSSION
mation have been developed for the treatment of patients.
-- Fig. 3 . Effect of SP-or MP-treatment for 66 weeks on osteoclast activation by measuring bone ALP in the serum. The serum from blood 1 ml was immediately prepared and 500 μl was used for ALP activity. All data are (*: p < 0.05, **: p < 0.01, ***: p < 0.001) PBS; phosphate buffered saline, SP; Substance-P, MP; methylprednisolone (n = 5).
Bone ALP (U/L)
Vol 0.01, ***: p < 0.001). Vol. 39 No. 3 injury (Jiang et al., 2012 (Jiang et al., , 2013 ) and a BMSC mobilizer in the alkali burn model propose -tion and facilitate tissue repair. In order to assess SP's potential medical application, its safety on the development of hyperglycemia and osteoporosis, major unwanted side effects observed in the long-term usage of steroids, is strategically considered in advance. This study supports the safety of SP in long-term usage at the aspects of hyperglycemia and osteoporosis, in comparison to the conventional immunosuppressive drugs DEX and MP.
Long-term usage or high dose of steroids provokes be the result of impairment of multiple pathways including beta cell dysfunctions and insulin resistance. Steroidprotocols, except for insulin treatment coincident with meals (Angelopoulos et al., 2003; Hwang and Weiss, 2013) . During the same treatment period, while DEX and MP had revealed unstable blood glucose level as predicted, SP-treated group had constant level of blood glucose, indicating the safety of SP in glucose regulation and furthermore, possibility to be developed as an efficient wound healing agent or a stem cell stimulant based on glucose tolerance test may be necessary. Histological and micro-CT analysis of femurs from SP-or MP-injected group for 66 weeks clearly revealed that SP did not cause such side effect as the bone weakness but MP, currently used in neurological disorder and spinal cord injury, showed obvious sign of osteoporosis, even though much weaker side effect was observed than that of DEX. MP's effect on the bone weakness was mainthickness in the TBA zone. As supported by the data in this study that bone ALP in the serum was much higher in MP-injected group, approximately 40% higher than the PBS-injected control as well as by previous report (Kress et al., 1999) , increased osteoclast activation may be one of possible mechanism for MP-mediated osteoporosis. On the contrary, SP-injection did not alter the ALP level in the serum but markedly increased the bone density and collagen deposition in the TBA, suggesting increased osteogenesis by SP injection. SP treatment for the longterm may not cause the bone weakness under the same treatment schedule of MP and can be proposed for dualthe early stage of wound healing and then as a mobilizer of reparative stem cells from the bone marrow to aid nonhealing or chronic wounds.
Although mechanism for SP-mediated osteogenesis under normal physiological condition remains to be determined, recent several reports (Kan et al., 2011; Salisbury et al., 2011; Wang et al., 2009) proposed the importance of neuro-inflammatory molecules such as SP or calcitonin gene related peptide (CGRP) in overactive BMP-2 involved in recruitment of mast cells, which then create microenvironment conductive for heterotypic bone formation. Additionally, importance of SP-TRPV1 signaling in the HO development was further supported by the data which are not functional for sensory neuron (Salisbury et al., 2011) . Even though SP's possible involvement in the overactive BMP-mediated HO was elucidated, the higher bone density and no change in the bone ALP in the longterm SP-injected group strongly suggest positive role of SP on the osteogenesis. Further studies employing the application of SP for the bone diseases such as bone frac--ciency on the regeneration of bone tissue and its mechanism of action.
